387 related articles for article (PubMed ID: 25962694)
1. Obesity as an independent risk factor for decreased survival in node-positive high-risk breast cancer.
Scholz C; Andergassen U; Hepp P; Schindlbeck C; Friedl TW; Harbeck N; Kiechle M; Sommer H; Hauner H; Friese K; Rack B; Janni W
Breast Cancer Res Treat; 2015 Jun; 151(3):569-76. PubMed ID: 25962694
[TBL] [Abstract][Full Text] [Related]
2. Obesity is an independent prognostic factor of decreased pathological complete response to neoadjuvant chemotherapy in breast cancer patients.
Karatas F; Erdem GU; Sahin S; Aytekin A; Yuce D; Sever AR; Babacan T; Ates O; Ozisik Y; Altundag K
Breast; 2017 Apr; 32():237-244. PubMed ID: 27318645
[TBL] [Abstract][Full Text] [Related]
3. The prognostic impact of obesity on molecular subtypes of breast cancer in premenopausal women.
Turkoz FP; Solak M; Petekkaya I; Keskin O; Kertmen N; Sarici F; Arik Z; Babacan T; Ozisik Y; Altundag K
J BUON; 2013; 18(2):335-41. PubMed ID: 23818343
[TBL] [Abstract][Full Text] [Related]
4. Effect of obesity on disease-free and overall survival in node-positive breast cancer patients in a large French population: a pooled analysis of two randomised trials.
Ladoire S; Dalban C; Roché H; Spielmann M; Fumoleau P; Levy C; Martin AL; Ecarnot F; Bonnetain F; Ghiringhelli F
Eur J Cancer; 2014 Feb; 50(3):506-16. PubMed ID: 24315625
[TBL] [Abstract][Full Text] [Related]
5. Impact of the obesity on lymph node status in operable breast cancer patients.
Keskin O; Aksoy S; Babacan T; Sarici F; Kertmen N; Solak M; Turkoz FP; Arik Z; Esin E; Petekkaya I; Altundag K
J BUON; 2013; 18(4):824-30. PubMed ID: 24344004
[TBL] [Abstract][Full Text] [Related]
6. Obesity is an independent prognostic variable in colon cancer survivors.
Sinicrope FA; Foster NR; Sargent DJ; O'Connell MJ; Rankin C
Clin Cancer Res; 2010 Mar; 16(6):1884-93. PubMed ID: 20215553
[TBL] [Abstract][Full Text] [Related]
7. The effect of body mass index on overall and disease-free survival in node-positive breast cancer patients treated with docetaxel and doxorubicin-containing adjuvant chemotherapy: the experience of the BIG 02-98 trial.
de Azambuja E; McCaskill-Stevens W; Francis P; Quinaux E; Crown JP; Vicente M; Giuliani R; Nordenskjöld B; Gutiérez J; Andersson M; Vila MM; Jakesz R; Demol J; Dewar J; Santoro A; Lluch A; Olsen S; Gelber RD; Di Leo A; Piccart-Gebhart M
Breast Cancer Res Treat; 2010 Jan; 119(1):145-53. PubMed ID: 19731015
[TBL] [Abstract][Full Text] [Related]
8. Impact of body mass index on neoadjuvant treatment outcome: a pooled analysis of eight prospective neoadjuvant breast cancer trials.
Fontanella C; Lederer B; Gade S; Vanoppen M; Blohmer JU; Costa SD; Denkert C; Eidtmann H; Gerber B; Hanusch C; Hilfrich J; Huober J; Schneeweiss A; Paepke S; Jackisch C; Mehta K; Nekljudova V; Untch M; Neven P; von Minckwitz G; Loibl S
Breast Cancer Res Treat; 2015 Feb; 150(1):127-39. PubMed ID: 25677740
[TBL] [Abstract][Full Text] [Related]
9. Impact of body mass index on clinical outcomes in triple-negative breast cancer.
Ademuyiwa FO; Groman A; O'Connor T; Ambrosone C; Watroba N; Edge SB
Cancer; 2011 Sep; 117(18):4132-40. PubMed ID: 21387276
[TBL] [Abstract][Full Text] [Related]
10. Body mass index (BMI) and breast cancer: impact on tumor histopathologic features, cancer subtypes and recurrence rate in pre and postmenopausal women.
Biglia N; Peano E; Sgandurra P; Moggio G; Pecchio S; Maggiorotto F; Sismondi P
Gynecol Endocrinol; 2013 Mar; 29(3):263-7. PubMed ID: 23174088
[TBL] [Abstract][Full Text] [Related]
11. The association between body mass index and immunohistochemical subtypes in breast cancer.
Sahin S; Erdem GU; Karatas F; Aytekin A; Sever AR; Ozisik Y; Altundag K
Breast; 2017 Apr; 32():227-236. PubMed ID: 27756509
[TBL] [Abstract][Full Text] [Related]
12. Endocrine therapy in obese patients with primary breast cancer: another piece of evidence in an unfinished puzzle.
Wolters R; Schwentner L; Regierer A; Wischnewsky M; Kreienberg R; Wöckel A
Breast Cancer Res Treat; 2012 Feb; 131(3):925-31. PubMed ID: 22080246
[TBL] [Abstract][Full Text] [Related]
13. [Body mass index and cancer incidence:a prospective cohort study in northern China].
Guo L; Li N; Wang G; Su K; Li F; Yang L; Ren J; Chang S; Chen S; Wu S; He J; Dai M
Zhonghua Liu Xing Bing Xue Za Zhi; 2014 Mar; 35(3):231-6. PubMed ID: 24831616
[TBL] [Abstract][Full Text] [Related]
14. Randomized, phase III trial of sequential epirubicin and docetaxel versus epirubicin alone in postmenopausal patients with node-positive breast cancer.
Coombes RC; Bliss JM; Espie M; Erdkamp F; Wals J; Tres A; Marty M; Coleman RE; Tubiana-Mathieu N; den Boer MO; Wardley A; Kilburn LS; Cooper D; Thomas MW; Reise JA; Wilkinson K; Hupperets P
J Clin Oncol; 2011 Aug; 29(24):3247-54. PubMed ID: 21768453
[TBL] [Abstract][Full Text] [Related]
15. Does obesity have an effect on outcomes in triple-negative breast cancer?
Mowad R; Chu QD; Li BD; Burton GV; Ampil FL; Kim RH
J Surg Res; 2013 Sep; 184(1):253-9. PubMed ID: 23768767
[TBL] [Abstract][Full Text] [Related]
16. Lymph node ratio and pN staging in patients with node-positive breast cancer: a report from the Korean breast cancer society.
Ahn SH; Kim HJ; Lee JW; Gong GY; Noh DY; Yang JH; Jung SS; Park HY
Breast Cancer Res Treat; 2011 Nov; 130(2):507-15. PubMed ID: 21858659
[TBL] [Abstract][Full Text] [Related]
17. Nuclear karyopherin alpha2 expression predicts poor survival in patients with advanced breast cancer irrespective of treatment intensity.
Gluz O; Wild P; Meiler R; Diallo-Danebrock R; Ting E; Mohrmann S; Schuett G; Dahl E; Fuchs T; Herr A; Gaumann A; Frick M; Poremba C; Nitz UA; Hartmann A
Int J Cancer; 2008 Sep; 123(6):1433-8. PubMed ID: 18561322
[TBL] [Abstract][Full Text] [Related]
18. Impact of body mass index (BMI) on the prognosis of high-risk early breast cancer (EBC) patients treated with adjuvant chemotherapy.
Gennari A; Amadori D; Scarpi E; Farolfi A; Paradiso A; Mangia A; Biglia N; Gianni L; Tienghi A; Rocca A; Maltoni R; Antonucci G; Bruzzi P; Nanni O
Breast Cancer Res Treat; 2016 Aug; 159(1):79-86. PubMed ID: 27460638
[TBL] [Abstract][Full Text] [Related]
19. BCIRG 001 molecular analysis: prognostic factors in node-positive breast cancer patients receiving adjuvant chemotherapy.
Dumontet C; Krajewska M; Treilleux I; Mackey JR; Martin M; Rupin M; Lafanechère L; Reed JC
Clin Cancer Res; 2010 Aug; 16(15):3988-97. PubMed ID: 20576719
[TBL] [Abstract][Full Text] [Related]
20. Obesity as an adverse prognostic factor for patients receiving adjuvant chemotherapy for breast cancer.
Bastarrachea J; Hortobagyi GN; Smith TL; Kau SW; Buzdar AU
Ann Intern Med; 1994 Jan; 120(1):18-25. PubMed ID: 8250452
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
